1. Home
  2. STOK
  3. STOK News

Latest Stoke Therapeutics Inc. (STOK) News on November 15, 2025

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
STOK

Business Wire

16 days ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

STOK

MT Newswires

a month ago

Stoke Therapeutics Insider Sold Shares Worth $750,000, According to a Recent SEC Filing

Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?
STOK

Zacks

a month ago

Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?

STOK

MT Newswires

a month ago

Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome

Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome
STOK

Simply Wall St.

a month ago

Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
STOK

GlobeNewswire

a month ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
STOK

Business Wire

a month ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?
STOK

Zacks

a month ago

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?

STOK

MT Newswires

2 months ago

Ultragenyx Names Eric Olson as Chief Business Officer

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Business Wire

2 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
STOK

PR Newswire

2 months ago

MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board

Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug
STOK

Simply Wall St.

2 months ago

Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STOK

Business Wire

5 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
STOK

Business Wire

6 months ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
STOK

Zacks

6 months ago

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
STOK

Business Wire

6 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
STOK

Zacks

6 months ago

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
STOK

Investor's Business Daily

6 months ago

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?

Is There An Opportunity With Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 49% Undervaluation?
STOK

Simply Wall St.

7 months ago

Is There An Opportunity With Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 49% Undervaluation?

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
STOK

Zacks

7 months ago

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
STOK

Zacks

7 months ago

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
STOK

Business Wire

7 months ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
STOK

Simply Wall St.

8 months ago

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Stoke Therapeutics Stock Slips as CEO Steps Down
STOK

Investopedia

8 months ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
STOK

Zacks

8 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke CEO exits; Medicare drug price talks advance
STOK

BioPharma Dive

8 months ago

Stoke CEO exits; Medicare drug price talks advance

STOK

MT Newswires

8 months ago

Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
STOK

Business Wire

8 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Stoke Therapeutics Announces CEO Transition
STOK

Business Wire

8 months ago

Stoke Therapeutics Announces CEO Transition

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
STOK

Zacks

8 months ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?
STOK

Zacks

8 months ago

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Stoke Therapeutics to Present at Upcoming Investor Conferences in March
STOK

Business Wire

9 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
STOK

Pharmaceutical Technology

9 months ago

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
STOK

Benzinga

9 months ago

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

STOK

MT Newswires

9 months ago

HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating

STOK

MT Newswires

9 months ago

Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
STOK

Business Wire

9 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug
STOK

BioPharma Dive

9 months ago

Biogen buys rights to Stoke’s rare epilepsy drug

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
STOK

Zacks

9 months ago

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?

The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%
STOK

Simply Wall St.

10 months ago

The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK

Zacks

10 months ago

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STOK

Business Wire

10 months ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
STOK

BioPharma Dive

10 months ago

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

STOK

MT Newswires

10 months ago

Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial

STOK

MT Newswires

10 months ago

Wedbush Raises Stoke Therapeutics' Price Target to $19 From $17, Keeps Outperform Rating

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
STOK

Business Wire

10 months ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
STOK

Business Wire

10 months ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
STOK

Zacks

a year ago

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
STOK

Zacks

a year ago

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

STOK

MT Newswires

a year ago

Chardan Initiates Coverage on Stoke Therapeutics With Buy Rating

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
STOK

Simply Wall St.

a year ago

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

STOK

MT Newswires

a year ago

Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
STOK

Business Wire

a year ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
STOK

Zacks

a year ago

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

STOK

MT Newswires

a year ago

Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
STOK

Business Wire

a year ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
STOK

Business Wire

a year ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
STOK

Pharma Voice

a year ago

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
STOK

Zacks

a year ago

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
STOK

Zacks

a year ago

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues
STOK

Simply Wall St.

a year ago

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
STOK

Zacks

a year ago

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
STOK

Business Wire

a year ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
STOK

Zacks

a year ago

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
STOK

Zacks

a year ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Stoke Therapeutics assumed with an Outperform at Leerink
STOK

TipRanks

a year ago

Stoke Therapeutics assumed with an Outperform at Leerink

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases
STOK

Insider Monkey

a year ago

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

STOK

MT Newswires

a year ago

Stoke Therapeutics Files Mixed Shelf

STOK

GuruFocus.com

a year ago

Skorpios Trust Reduces Stake in Stoke Therapeutics Inc

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
STOK

Business Wire

a year ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
STOK

Business Wire

a year ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
STOK

Business Wire

a year ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September
STOK

Business Wire

a year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Business Wire

a year ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
STOK

Simply Wall St.

a year ago

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold
STOK

Clinical Trials Arena

a year ago

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
STOK

Zacks

a year ago

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
STOK

Business Wire

a year ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
STOK

Zacks

a year ago

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%
STOK

Simply Wall St.

a year ago

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Business Wire

a year ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Business Wire

a year ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
STOK

Simply Wall St.

a year ago

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

STOK

MT Newswires

a year ago

Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders

Stoke Therapeutics to Present at Upcoming Investor Conferences in June
STOK

Business Wire

a year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
STOK

GuruFocus.com

a year ago

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

STOK

MT Newswires

a year ago

Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
STOK

Business Wire

a year ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
STOK

GuruFocus.com

2 years ago

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

STOK

MT Newswires

2 years ago

Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations
STOK

Simply Wall St.

2 years ago

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
STOK

Zacks

2 years ago

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
STOK

Business Wire

2 years ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

STOK

MT Newswires

2 years ago

Stoke Therapeutics Appoints Thomas Leggett CFO

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
STOK

Zacks

2 years ago

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
STOK

Business Wire

2 years ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
STOK

Zacks

2 years ago

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
STOK

Business Wire

2 years ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STOK

Business Wire

2 years ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
STOK

Business Wire

2 years ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Share on Social Networks: